

REMARKS

This paper is responsive to the Office communication mailed on March 17, 2009. Claims 1–33 are pending in this application. Claims 22–33 are withdrawn from consideration by the Examiner as being directed toward a non-elected invention. The specification is amended herein to provide sequence identifiers for all nucleotide sequences in excess of ten nucleotides in length in the application, claims 13, 14, 29 and 30 are amended herein to provide sequence identifiers for the nucleotide sequences recited in these claims, and claim 33 is amended herein to correct an inadvertent error in the dependency of this claim. No new matter has been added by these amendments. In view of the foregoing, Applicants believe that the application complies with the sequence rules as set forth in 37 C.F.R. § 1.821–1.825, and that the present application is in condition for examination on the merits, which action is earnestly requested.

No fee is believed due with this response. However, the Commissioner is authorized to charge any deficiency or credit any overpayment to Deposit Account No. 50-0220.

Respectfully submitted,




Mary L. Miller
Registration No.: 39,303

USPTO Customer No. 20792
Myers Bigel Sibley & Sajovec
Post Office Box 37428
Raleigh, North Carolina 27627
Telephone: 919/854-1400
Facsimile: 919/854-1401

CERTIFICATION OF ELECTRONIC TRANSMISSION

I hereby certify that this correspondence is being transmitted via the Office electronic filing system in accordance with § 1.6(a)(4) to the U.S. Patent and Trademark Office on April 15, 2009.



Claire Wimberly